Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.

[1]  J. Cohn,et al.  Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality? , 2009, Journal of cardiac failure.

[2]  Marc A Pfeffer,et al.  Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials , 2006, Circulation.

[3]  P. Poole‐Wilson,et al.  A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). , 2006, Journal of the American College of Cardiology.

[4]  Gerry Gray,et al.  Key issues in end point selection for heart failure trials: composite end points. , 2005, Journal of cardiac failure.

[5]  L. Zanolla,et al.  Selection of endpoints for heart failure clinical trials , 2003, European journal of heart failure.

[6]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[7]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[8]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[9]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[10]  J. Cleland.  How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients’ clinical journey , 2002, European journal of heart failure.

[11]  S. Thompson,et al.  Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.

[12]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[13]  J. Cohn,et al.  Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. , 1999, The American journal of cardiology.

[14]  C. Furberg,et al.  Surrogates, semantics, and sensible public policy. , 1997, Circulation.

[15]  J. Lubsen,et al.  Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. , 1986, British medical journal.